Literature DB >> 19066840

[The role of radical lymphadenectomy. Experiences from the AGO Ovarian Cancer Study Group].

P Wimberger1, R Kimmig.   

Abstract

Radicality in primary surgical management in gynaecological cancers, especially in ovarian cancer, is the most important factor influencing patient survival. Postoperative residual tumour is one of the most important prognostic factors in ovarian cancer. Radical pelvic and paraaortic lymphadenectomy is recommended in cases of complete resection because of the high incidence of lymph node metastases, especially in the high paraaortic region. A multicenter, prospective randomised study of advanced ovarian cancer by the AGO Ovarian Cancer Study Group is planned to analyse the therapeutic impact of systematic lymphadenectomy in ovarian cancer.

Entities:  

Mesh：

Year:  2009        PMID： 19066840     DOI： 10.1007/s00120-008-1755-9

Source DB:  PubMed          Journal:  Urologe A        ISSN： 0340-2592            Impact factor:   0.639


  16 in total

1.  Systematic aortic and pelvic lymphadenectomy versus resection of bulky nodes only in optimally debulked advanced ovarian cancer: a randomized clinical trial.

Authors:  Pierluigi Benedetti Panici; Angelo Maggioni; Neville Hacker; Fabio Landoni; Sven Ackermann; Elio Campagnutta; Karl Tamussino; Raimund Winter; Antonio Pellegrino; Stefano Greggi; Roberto Angioli; Natalina Manci; Giovanni Scambia; Tiziana Dell'Anna; Roldano Fossati; Irene Floriani; Rita S Rossi; Roberto Grassi; Giuseppe Favalli; Francesco Raspagliesi; Diana Giannarelli; Luca Martella; Costantino Mangioni
Journal:  J Natl Cancer Inst       Date:  2005-04-20       Impact factor: 13.506

2.  Early stage ovarian cancer: the Italian contribution to clinical research. An update.

Authors:  G Favalli; F Odicino; V Torri; S Pecorelli
Journal:  Int J Gynecol Cancer       Date:  2001       Impact factor: 3.437

3.  Prognostic importance of degree of differentiation and cyst rupture in stage I invasive epithelial ovarian carcinoma.

Authors:  I Vergote; J De Brabanter; A Fyles; K Bertelsen; N Einhorn; P Sevelda; M E Gore; J Kaern; H Verrelst; K Sjövall; D Timmerman; J Vandewalle; M Van Gramberen; C G Tropé
Journal:  Lancet       Date:  2001-01-20       Impact factor: 79.321

4.  Assessment of metastases to aortic and pelvic lymph nodes in epithelial ovarian carcinoma. A proposal for essential sites for lymph node biopsy.

Authors:  T Onda; H Yoshikawa; H Yokota; T Yasugi; Y Taketani
Journal:  Cancer       Date:  1996-08-15       Impact factor: 6.860

Review 5.  Advances in the management of endometrial adenocarcinoma. A review.

Authors:  William P Irvin; Laural W Rice; Ross S Berkowitz
Journal:  J Reprod Med       Date:  2002-03       Impact factor: 0.142

6.  Systematic pelvic and paraaortic lymphadenectomy for advanced ovarian cancer: prognostic significance of node metastases.

Authors:  F di Re; G Baiocchi; R Fontanelli; G Grosso; L Cobellis; F Raspagliesi; E di Re
Journal:  Gynecol Oncol       Date:  1996-09       Impact factor: 5.482

Review 7.  Pelvic and para-aortic lymphadenectomy in cancer of the ovary.

Authors:  F Di Re; R Fontanelli; F Raspagliesi; E Di Re
Journal:  Baillieres Clin Obstet Gynaecol       Date:  1989-03

8.  Drug sensitivity-related benefit of systematic lymphadenectomy during cytoreductive surgery in optimally debulked stages IIIc and IV ovarian cancer.

Authors:  Seiji Isonishi; Shigeki Niimi; Hiroshi Sasaki; Kazunori Ochiai; Makoto Yasuda; Tadao Tanaka
Journal:  Gynecol Oncol       Date:  2004-06       Impact factor: 5.482

9.  Lymph node involvement in epithelial ovarian cancer: analysis of 276 pelvic and paraaortic lymphadenectomies and surgical implications.

Authors:  Philippe Morice; Franklin Joulie; Sophie Camatte; David Atallah; Roman Rouzier; Patricia Pautier; Christophe Pomel; Catherine Lhommé; Pierre Duvillard; Damienne Castaigne
Journal:  J Am Coll Surg       Date:  2003-08       Impact factor: 6.113

10.  Systematic pelvic and para-aortic lymphadenectomy in advanced ovarian cancer patients with no residual intraperitoneal disease.

Authors:  C Scarabelli; A Gallo; M C Visentin; V Canzonieri; A Carbone; A Zarrelli
Journal:  Int J Gynecol Cancer       Date:  1997-01       Impact factor: 3.437
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.